Sugi Predict

Sugi Predict / Compounds / SCHEMBL3830401

SCHEMBL3830401

SCHEMBL3830401

O=C(O)NC1(CO)CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 1/20 0.41
▸ MME P08473 1/20 0.36
▸ ANO1 Q5XXA6 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ RAF1 P04049 1/20 0.33
▸ BRAF P15056 1/20 0.33
▸ GLA P06280 1/20 0.31
▸ LMNA P02545 1/20 0.30
▸ DGAT2 Q96PD7 1/20 0.30
▸ BTK Q06187 1/20 0.30
▸ ALOX15 P16050 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19749002 0.93 MME (0.38) DPP4MMEANO1ALDH1A1RAF1
SCHEMBL3151070 0.84 — —
SCHEMBL12096373 0.84 ANO1 (0.35) DPP4ANO1
SCHEMBL25233795 0.82 DPP4 (0.33) DPP4
SCHEMBL14842130 0.82 KDM4E (0.31) DPP4ALDH1A1LMNATSHR
SCHEMBL15461395 0.82 DPP4 (0.40) DPP4MMEANO1ALDH1A1RAF1
SCHEMBL18131263 0.80 MME (0.41) DPP4MME
SCHEMBL9104945 0.80 MME (0.45) DPP4MMEALDH1A1
SCHEMBL3675526 0.78 MME (0.44) DPP4MMEALDH1A1LMNATSHR
SCHEMBL18131294 0.78 EPHX1 (0.36) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4257191-A2 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2023-10-11 — — EP disclosed
EP-3472149-B1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2023-08-30 — — EP disclosed
US-20230002392-A1 Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors INCYTE CORPORATION 2023-01-05 — — US disclosed
US-11377439-B2 Heterocyclic prolinamide derivatives Orion Ophthalmology LLC (US) 2022-07-05 — — US disclosed
US-11261191-B2 Imidazotriaines and imidazopyrimidines as kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2022-03-01 — — US disclosed
US-20200317680-A1 Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors INCYTE HOLDINGS CORPORATION 2020-10-08 — — US disclosed
US-10738052-B2 Imidazotriaines and imidazopyrimidines as kinase inhibitors INCYTE HOLDINGS CORPORATION (US) 2020-08-11 — — US disclosed
US-20190322645-A1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2019-10-24 — — US disclosed
EP-3472149-A1 HETEROCYCLIC PROLINAMIDE DERIVATIVES ORION OPTHALMOLOGY LLC (US) 2019-04-24 — — EP disclosed
EP-3443958-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS Incyte Holdings Corporation (US) 2019-02-20 — — EP disclosed
US-20170044182-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF FORUM PHARMACEUTICALS INC. 2017-02-16 — — US disclosed
US-20160326178-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS INCYTE CORPORATION 2016-11-10 — — US disclosed
WO-2016162325-A1 SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-A]PYRAZIN-1 (2H)-ONE DERIVATIVES AS KINASE INHIBITORS ASTRAZENECA AB (SE) 2016-10-13 — — WO disclosed
EP-3034075-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS Incyte Holdings Corporation (US) 2016-06-22 — — EP disclosed
EP-2497470-B1 Imidazotriazines and imidazopyrimidines as kinase inhibitors INCYTE CORP (US) 2015-10-28 — — EP disclosed
US-8461330-B2 Imidazotriazines and imidazopyrimidines as kinase inhibitors INCYTE CORPORATION (US) 2013-06-11 — — US disclosed
EP-2099447-B1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS INCYTE CORP (US) 2012-11-07 — — EP disclosed
EP-2497470-A1 Imidazotriazines and imidazopyrimidines as kinase inhibitors Incyte Corporation (US) 2012-09-12 — — EP disclosed
EP-2099447-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS Incyte Corporation (US) 2009-09-16 — — EP disclosed
WO-2008064157-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS INCYTE CORPORATION (US) 2008-05-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044182-A1 FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF SMN1; SMN2, FUS, SYNCRIP DPP4 1451/4885MME 777/4885ANO1 4692/4885
US-20160326178-A1 IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS ERBB2, MERTK, ABL1 DPP4 471/4885MME 3590/4885ANO1 2988/4885
US-20230002392-A1 Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors ERBB2, MERTK, ABL1 DPP4 471/4885MME 3590/4885ANO1 2988/4885
US-20190322645-A1 HETEROCYCLIC PROLINAMIDE DERIVATIVES HTRA1, ALDH1A2, HTRA2 DPP4 37/4885MME 367/4885ANO1 2580/4885
US-20200317680-A1 Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors MET, RET, ERBB2 DPP4 472/4885MME 3322/4885ANO1 3744/4885
US-11261191-B2 Imidazotriaines and imidazopyrimidines as kinase inhibitors MET, RET, ERBB2 DPP4 472/4885MME 3322/4885ANO1 3744/4885
US-11377439-B2 Heterocyclic prolinamide derivatives HTRA1, ALDH1A2, HTRA2 DPP4 37/4885MME 367/4885ANO1 2580/4885
US-10738052-B2 Imidazotriaines and imidazopyrimidines as kinase inhibitors MET, RET, ERBB2 DPP4 472/4885MME 3322/4885ANO1 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.